Life Sciences M&A Insurance: A Guide for Buyers and Sellers

Insurance arrives late in most life sciences M&A processes. The financial diligence, legal diligence, and regulatory diligence run on parallel tracks for weeks before the insurance review starts, and by the time it does, the structural decisions that affect coverage outcomes have often already been made. Reversing those decisions late in the process is expensive when it is possible at all.

This is particularly true for life sciences transactions. The insurance program at a regulated company is not interchangeable with a generic operating-company program. Products liability is occurrence-based and follows the product over its field life. Claims-made lines (D&O, EPLI, Tech E&O, cyber where claims-made) require explicit tail or run-off coverage at close. Cyber and HIPAA exposure transfers with the data, and the BAA inventory and regulatory standing transfer with the entity in a stock deal. The structure of the transaction (asset vs stock vs reverse merger vs JV) determines which obligations the buyer assumes and which the seller retains.

This walks through how insurance shows up in life sciences M&A diligence, the difference between asset and stock transaction implications, what each side should prepare, how R&W insurance fits the picture, and the specific exposures that surface in life sciences deals more often than in generic M&A.

How Insurance Diligence Actually Runs

In a typical life sciences M&A process, the buyer’s diligence team requests the seller’s insurance program in the first round of document requests. The standard package includes:

• Schedule of all current policies (lines, carriers, limits, retentions, effective dates, premiums).
• Certificates of insurance for all in-force policies.
• Loss runs for the last 3 to 5 years across all lines.
• Description and current status of all open and recent claims.
• Description of any regulatory matters open or recently closed (FDA Warning Letters, OCR investigations, CLIA findings, state insurance department matters).
• Broker compensation arrangements and any non-standard placement structures.
• BAA inventory where the company is HIPAA-regulated.
• Any prior tail coverage purchases or pending acquisition-related coverage decisions.

The buyer’s insurance advisor reviews this material against the buyer’s own program structure and identifies gaps, redundancies, and any items that affect deal value or transition planning. The output is usually a memo that flows into the broader diligence summary.

What separates a strong insurance diligence process from a weak one is how the memo translates findings into specific deal-document language. Reps and warranties about insurance, indemnification carve-outs around insurance recoveries, and the treatment of in-place policies post-close all sit in the purchase agreement. Generic insurance reps that fail to address life sciences specifics are a frequent source of post-close dispute.

Asset Sale vs Stock Sale: The Coverage Implications

The transaction structure determines which insurance program responds to pre-close events after the close.

Stock sale. The buyer acquires the entity, including its insurance policies and historical liabilities. In-force policies generally remain in force, though most policies contain change-of-control provisions that require carrier consent and often trigger underwriting reconsideration. Loss runs and claims history transfer with the company. Tail coverage decisions for claims-made lines may or may not be required depending on whether the buyer carries equivalent coverage post-close. Successor liability for products is governed by the products policies in effect at the time of injury, which means the seller’s historical products program is the relevant coverage for any pre-close injury that surfaces post-close.

Asset sale. The buyer acquires specified assets and assumes specified liabilities. The seller entity (often a shell after close) retains everything not assumed. Claims-made policies in the seller entity require tail coverage purchases. Products liability for products sold pre-close generally remains with the seller’s policies, though successor liability theories under state law can produce direct buyer exposure for certain pre-close products. The cleanest structure: seller buys tail on all claims-made lines at close, and the buyer’s program responds to the post-close operations.

Reverse merger and other structures. Less standard structures (reverse merger, F-reorg, JV) introduce additional complexity around which entity retains historical liability, which policies remain in force, and which tail purchases are required. Each transaction should be reviewed against the actual structure rather than treated as fitting one of the two standard cases.

What Sellers Should Prepare

A seller entering an M&A process benefits from cleaning up the insurance posture before the diligence request arrives.

Loss runs and claims history. Order loss runs from each carrier 90 days before the diligence package is due. Reviewing them in advance allows the seller to add context to any losses that look unusual without it. Loss runs delivered late, or delivered without context, attract buyer concern.

Policy schedule and certificates. A current, accurate schedule of all in-force policies, with COIs on file, is the baseline. Missing or stale documentation looks like operational sloppiness to the buyer’s diligence team.

Regulatory standing summary. For FDA-regulated, HIPAA-regulated, or CLIA-regulated companies, a current summary of regulatory standing (any open inspections, recent Warning Letters, OCR matters, CAP inspection findings) avoids surprises during diligence. Buyers will surface this material independently; a seller’s transparent summary affects how the findings are weighted.

Tail coverage analysis. For claims-made lines, the seller should understand what tail coverage will cost and how it gets purchased at close. Many policies include tail provisions in the form (typically 3, 6, or unlimited years at a multiple of the prior annual premium). The cost factors directly into transaction economics.

Open claims status. Any open or recent claims should be summarized with current status, reserves, and the carrier’s defense posture. Closed claims need to be available in the data room as well; buyers will ask.

Anti-bribery, sanctions, and export controls posture. Less obvious in domestic life sciences deals, but increasingly common in diligence. International distribution agreements, GCP/GMP-relevant suppliers in sanctioned jurisdictions, and any FCPA-relevant compensation arrangements affect the insurance review and the broader diligence.

Cyber and HIPAA documentation. BAA inventory, current Security Rule risk analysis, breach history, and notification log. Particularly important for HIPAA-regulated entities, where OCR enforcement posture under the Risk Analysis Initiative makes any documented analysis gaps a leading diligence concern.

What Buyers Should Prepare

A buyer also has insurance-side preparation that affects how cleanly the post-close program operates.

Program integration plan. The buyer’s existing insurance program may or may not be able to extend to the acquired operations. For a serial acquirer, a documented integration framework saves repeated work. For a first-time acquirer in life sciences, the integration questions are often new and need explicit attention.

Day-one coverage continuity. The acquired entity needs continuous coverage on all material lines from the moment of close. Gaps even of a single day can produce uninsured exposure for events that span the close. Bind orders, COIs to be issued at close, and any necessary endorsements should be lined up in advance.

Successor liability assessment. Particularly for medical device acquisitions, the buyer’s products liability advisor should evaluate the seller’s product portfolio for ongoing exposure that will attach to the buyer’s program post-close. The legacy products line is not extinguished at close; injuries arising from pre-close units can produce claims years later. For acquisitions of manufacturers with active recall exposure, the recall coverage gap analysis should be part of the diligence package.

R&W placement strategy. If R&W is going to be part of the structure, the placement timing matters. R&W underwriters need 2 to 4 weeks lead time, sometimes more for complex life sciences targets. Late placement requests produce constrained outcomes.

Cyber and HIPAA program assessment. The buyer should evaluate whether the target’s cyber and HIPAA program meets the buyer’s risk standards. Where the answer is no, the integration plan should include the remediation pathway and the budget for it.

R&W Insurance: How It Fits Life Sciences Deals

Representations and warranties insurance has become a standard feature of mid-market and larger life sciences M&A. Buy-side R&W is the dominant placement form. The policy responds to unknown breaches of the seller’s reps and warranties that surface after close.

The structure typically works as follows. The seller’s reps survive for a defined period (12 to 24 months typically for general reps; longer for fundamental reps and tax). The buyer’s indemnification rights against the seller are constrained, either to a smaller indemnification cap (lower than the R&W limit) or eliminated entirely except for fraud and fundamental reps. The R&W policy then sits as the buyer’s primary recourse for general reps breaches.

R&W placements have specific structural features in life sciences deals.

Diligence-driven exclusions. Anything that surfaces in diligence as a known or potential issue is excluded from R&W. The completeness and rigor of buyer diligence directly affects what the policy covers. A buyer who pushes hard on diligence finds more issues, which are then excluded, leaving the policy responding only to truly unknown breaches.

FDA and regulatory exclusions. Many R&W carriers carve out specific FDA-related representations, particularly around device safety, clinical trial conduct, and post-market surveillance. The wording of these carve-outs is the active negotiation point in life sciences deals.

Data, privacy, and HIPAA exclusions. R&W carriers vary on how broadly they exclude HIPAA breaches. Some carve out only known breaches; others carve out a broader category of unknown HIPAA matters. The wording matters in a deal involving a HIPAA-regulated target.

Cybersecurity incident exclusions. Known and unknown cyber incidents are routinely carved out of R&W in technology and healthcare deals. The buyer’s cyber policy is the responsive line, with R&W playing a smaller role.

Loss components covered. R&W typically responds to direct loss (the diminution in value attributable to the breach) and reasonable expenses. Some policies include sub-limits for consequential damages or multiplied damages where the underlying reps make them recoverable.

Sub-limits and exclusions for specific reps. Reps around tax positions, transfer pricing, and certain regulatory matters often carry separate sub-limits or specific exclusions. Reading the policy form against the rep schedule is the placement review.

What Each Side Should Push on at Negotiation

Several specific items show up in the purchase agreement insurance section and produce post-close dispute when handled loosely.

Treatment of pre-close insurance recoveries. When the seller’s policy responds to a pre-close event that produces post-close indemnification, who keeps the recovery? Standard treatment: the buyer’s indemnification claim is offset by insurance recoveries actually received, but the buyer is not required to pursue insurance to mitigate. Tighter or looser wording is negotiable.

Cooperation in claim handling. Post-close cooperation between buyer and seller on legacy claims (provision of documents, witness availability, claim authority decisions) is often loosely drafted. Specific provisions on cooperation produce better outcomes when legacy claims actually surface.

Tail coverage allocation. Who pays for the tail coverage on the seller’s claims-made lines is a deal-specific economic decision. Where the buyer is acquiring the entity in a stock deal and the buyer’s program will cover go-forward, the buyer may or may not require tail purchase. Where the seller is required to buy tail, the cost should be specified in the purchase agreement rather than treated as a closing miscellaneous item.

Run-off D&O. Departing directors and officers usually require run-off coverage for personal liability for pre-close acts. The cost (typically 200% to 250% of the prior annual D&O premium for a 6-year tail) and the responsibility for purchase should be addressed in the purchase agreement.

Treatment of legacy products policies. Particularly for medical device sellers, the legacy products program responds to pre-close injuries. The policy schedule should be preserved, the carrier relationships should be addressed, and the documentation needed for post-close claim coordination should be in the data room.

Common Mistakes on Both Sides

Sellers underestimating tail coverage costs. Tail on claims-made lines can run materially. A seller modeling transaction proceeds without accounting for tail produces an unpleasant final-stage surprise.

Buyers treating insurance diligence as a checkbox. A surface-level insurance review that confirms policies exist, without engaging with wording, claim history, or regulatory standing, misses the issues that actually drive post-close coverage outcomes.

Either side delaying R&W placement. R&W timing is constrained by underwriter availability and the diligence completion. Late requests get late or constrained results.

Treating products liability as transferring cleanly. Successor liability for products sold pre-close does not extinguish at close. The buyer’s exposure to claims from pre-close products requires explicit attention in the purchase agreement and in the buyer’s go-forward program structure.

Skipping cyber and HIPAA integration planning. For HIPAA-regulated targets, the data security posture is a real exposure that surfaces in the buyer’s program post-close. Integration planning should anticipate the work, not treat it as a post-close operations item.

A Note on Placement

MedTech Coverage works with life sciences buyers and sellers on insurance diligence, R&W placement, tail and run-off coverage, and post-close program integration across all three life sciences segments. Coverage and diligence support are provided through Tower Street Insurance’s appointments with the specialty markets writing the life sciences segment and the R&W markets active in life sciences transactions.

If a transaction is approaching signing, if R&W placement timing is becoming a path-dependency, or if post-close program integration needs structured attention, a coverage review produces a working document calibrated to the transaction structure, the target’s regulatory posture, and the buyer’s go-forward insurance framework.